This just shows the severe confirmation bias that this group is engaged in. Fifteen people just 'liked' the silliness which you wrote and two people even said it contained 'Great Analysis' and no one even questioned the validity of the claims.
To clear up some facts when you erroneously attempt to claim that NUH IQ Buds will do the same thing as NTI's Mente autism device:
1) In regards to Auditory Processing Disorder (APD) Compensating and changing the environment by increasing volume of the sound will only make things a little easier for the patient but they will not
fix the auditory processing problem. The brain must be re-trained to process sound correctly and quickly. That is why neurofeedback which actively utilises personalised binaural beats through an eeg band is necessary so the beats can change beta and theta waves in accordance to the child's changing mind.
2) So to say that your IQ Bud will do the exact same thing as NTI (Neurotech International) Mente autism device is embarrassing. Your device does not read beta and theta waves actively through an eeg and then offer personalised binaural beats that change beta and theta waves in accordance to what the device is reading through the eeg. Your device also does not offer machine learning throughout the Neurofeedback process that actively learns about your childs brain waves over time and offers a therapy that neurologically changes you child's behaviour. Hence your IQ bud is not a Neurofeedback device - and not a treatment for autism nor does it actively treat auditory processing disorders by changing the individuals neurological waves.
3) Thus the IQ Bud is not even a treatment for autism so comparing NTI's Mente autism device to the IQ bud is silly. I might add - the IQ Bud only amplify noise into the ear of the child which is only a compensation approach to Neuro Processing Disorder and thus it is not even in the same field as NTI's Mente autism device. Accordingly, placing NTI's market cap on top of NUH's to show how much 'extra value' this announcement has today for NUH is desperate at best.
4) A hearing aid in a child's ear can do the exact same thing for a child in regards to the amplification compensation process. NUH is offering nothing new.
Here are some references so you can actually educate yourself on Autism, Auditory Processing Disorder and Neurofeedback:
[1]
Prevalence of autism spectrum disorders — autism and developmental disabilities monitoring network, 14 sites. United States.US National Library of Medicine
National Institutes of Health. 2008.
[2] Kouijzer, M., Gerrits, B., Congedo, M and Van Schie, T.
Neurofeedback improves executive functioning in children with autism spectrum disorders. Research in Autism Spectrum Disorders. 2009. Vol 3, Pp. 145–162.
[3] Coben, R and Padolsky, I. Assessment-guided neurofeedback for autistic spectrum disorders. Journal of Neurotherapy. 2007. Vol.11, P. 5–23.
[4] Kouijzer, M., Moora, J., Gerritsb, B., Buitelaarc, J and Van Schie, H.
Long-term effects of neurofeedback treatment in autism. A Behavioural Science Institute, Radboud University Nijmegen, Nijmegen, The Netherlands. Research in Autism Spectrum Disorders 3. 2009. P. 496–501. Elsivier Publishers.
[5] Jarusiewicz, B. Efficacy of Neurofeedback for Children in the Autistic Spectrum: A Pilot Study PhD. Pages 39- 49. 2008.
[6] Trevisan, A and P, Cavallari.
A Portable Sonified Neurofeedback Therapy for Autism Spectrum Disorder Patients - An Initial Evaluation. Journal of Neurological Disorders. AAT Research in conjuction with; University of California. USA. 2013.
[7] Trevisan, A., Cavallari, P., Caruana, N., Micallef, R and Attard, F.
Real-time sonified neurofeedback stimulation for the management & relaxation of patients on the autism spectrum. Journal of Brain Stimulation. Vol 8(2). March – April 2015.
[8] Neurotech International.
‘Clinical Trial: 12-week therapy session for initial cohort of subjects in US clinical trial nearing completion”.ASX market announcement dated: 29 May 2017.
[9] Neurotech International.
‘Clinical Trial Preliminary Outcomes: Outstanding preliminary results from US clinical study’, ASX market announcement dated: 27 September 2017.
[10] Neurotech International.
‘Neurotech Presentation at Cambridge Conference: Neurotech presentations at academic research conference in Cambridge, UK’, ASX market announcement dated: 28 September 2017.
(20min delay)